Cosgrove Lisa, Krimsky Sheldon, Vijayaraghavan Manisha, Schneider Lisa
University of Massachusetts, Boston, USA.
Psychother Psychosom. 2006;75(3):154-60. doi: 10.1159/000091772.
Increasing attention has been given to the transparency of potential conflicts of interest in clinical medicine and biomedical sciences, particularly in journal publishing and science advisory panels. The authors examined the degree and type of financial ties to the pharmaceutical industry of panel members responsible for revisions of the Diagnostic and Statistical Manual of Mental Disorders(DSM).
By using multimodal screening techniques the authors investigated the financial ties to the pharmaceutical industry of 170 panel members who contributed to the diagnostic criteria produced for the DSM-IV and the DSM-IV-TR.
Of the 170 DSM panel members 95 (56%) had one or more financial associations with companies in the pharmaceutical industry. One hundred percent of the members of the panels on 'Mood Disorders' and 'Schizophrenia and Other Psychotic Disorders' had financial ties to drug companies. The leading categories of financial interest held by panel members were research funding (42%), consultancies (22%) and speakers bureau (16%).
Our inquiry into the relationships between DSM panel members and the pharmaceutical industry demonstrates that there are strong financial ties between the industry and those who are responsible for developing and modifying the diagnostic criteria for mental illness. The connections are especially strong in those diagnostic areas where drugs are the first line of treatment for mental disorders. Full disclosure by DSM panel members of their financial relationships with for-profit entities that manufacture drugs used in the treatment of mental illness is recommended.
临床医学和生物医学科学中潜在利益冲突的透明度受到越来越多的关注，尤其是在期刊出版和科学咨询小组方面。作者调查了负责修订《精神疾病诊断与统计手册》（DSM）的小组成员与制药行业的财务关系程度和类型。
作者采用多模式筛选技术，调查了为DSM-IV和DSM-IV-TR制定诊断标准的170名小组成员与制药行业的财务关系。
在170名DSM小组成员中，95名（56%）与制药行业的公司有一个或多个财务关联。“情绪障碍”和“精神分裂症及其他精神病性障碍”小组的成员100%与制药公司有财务关系。小组成员持有的主要财务利益类别是研究资金（42%）、咨询（22%）和演讲局（16%）。
我们对DSM小组成员与制药行业之间关系的调查表明，该行业与负责制定和修改精神疾病诊断标准的人员之间存在密切的财务关系。在药物是精神障碍一线治疗手段的诊断领域，这种联系尤为紧密。建议DSM小组成员充分披露他们与生产用于治疗精神疾病药物的营利性实体的财务关系。
